NEUCA S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 897 PLN | +0.22% |
|
-0.88% | -3.03% |
| Mar. 23 | NEUCA S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | NEUCA S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| Sales 2024 * | 12.98B 3.22B | Sales 2025 * | 13.69B 3.39B | Capitalization | 4B 991M |
|---|---|---|---|---|---|
| Net income 2024 * | 178M 44.14M | Net income 2025 * | 230M 57.03M | EV / Sales 2024 * | 0.33 x |
| Net Debt 2024 * | 278M 68.93M | Net Debt 2025 * | 169M 41.98M | EV / Sales 2025 * | 0.3 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 4,633 |
| Yield 2024 * |
1.68% | Yield 2025 * |
2.23% | Free-Float | 34.15% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -1.10% | ||
| Current month | +0.34% | ||
| 1 month | -1.10% | ||
| 3 months | +4.31% | ||
| 6 months | +24.48% | ||
| Current year | -3.24% |
1 week
890.00
905.00
1 month
863.00911.00
Current year
790.00925.00
1 year
630.00940.00
3 years
527.00959.00
5 years
257.00959.00
10 years
182.10959.00
| Managers | Title | Age | Since |
|---|---|---|---|
Piotr Sucharski
CEO | Chief Executive Officer | - | 00-12-31 |
| Founder | - | 89-12-31 | |
Grzegorz Dzik
DFI | Director of Finance/CFO | - | 10-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | - | 89-12-31 | |
| Director/Board Member | 72 | 09-06-15 | |
| Founder | - | 89-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 7 M€ | +1.91% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 897 | +0.22% | 38 |
| 24-04-23 | 895 | -0.67% | 1,291 |
| 24-04-22 | 901 | +0.22% | 427 |
| 24-04-19 | 899 | -0.33% | 857 |
| 24-04-18 | 902 | -0.33% | 310 |
Delayed Quote Warsaw S.E., April 24, 2024 at 03:16 am EDT
More quotes
Neuca SA is a Poland-based company, which operates in the healthcare market. The Company is mainly involved in the distribution of drugs to pharmacies. It also operates in other sectors of the health market, such as production of drugs, supplements and cosmetics under its own brand, clinical trials, telemedicine, Information Technology (IT) solutions and e-commerce in the health care industry.
Sector
Pharmaceuticals
Calendar
2024-05-22
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
895
PLN
Average target price
974.7
PLN
Spread / Average Target
+8.90%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.24% | 993M | |
| +14.88% | 69.91B | |
| +5.13% | 8.32B | |
| +5.20% | 8.07B | |
| -20.43% | 7.97B | |
| +0.18% | 4.56B | |
| +16.98% | 4.31B | |
| -2.00% | 3.99B | |
| -3.23% | 3.87B | |
| +21.87% | 3.63B |
- Stock Market
- Equities
- NEU Stock
